Professional Documents
Culture Documents
treatment
Osteoporosis causes 1.5 million fractures and costs more than $14
billion annually in the United States alone; with these rates still
increasing, it is a worthy subject for discussion. This book is part of a
series intended to update endocrinologists about the latest
developments in osteoporosis. The combination of three themes
genetics, prevention, and treatment in a book of this size is a very
ambitious project in an area as exciting and fast-moving as
osteoporosis research.
The first section, consisting of four chapters, deals with genetics and
focuses primarily on skeletal morphogenesis, with a frightening list of
proteins and receptors, an excellent overview chapter on animal
models, and a scanty chapter on human disease. Although we are told
the importance of genetics, that the heritability of bone density may be
as high as 85 percent, there is no discussion of epidemiologic studies
that show that the risk of fractures is doubled in the daughters of
women with fractures, independently of density. There is no definition
of concepts such as heritability (also confusingly referred to as heredity
and inheritability). Many important questions remain unanswered,
including the potential clinical and preventive roles of the two main and
controversial candidate genes, the vitamin D receptor gene and the
collagen I gene, and how genes can be used therapeutically,
depending on their structural and metabolic properties. Should we be
looking for genes affecting the risk of fracture rather than its surrogate,
bone density? The book also suggests that there are only 5 to 10
osteoporosis genes, although it is likely that there are many more.
What about genes involved in bone turnover? How will the Human
Genome Mapping Project help researchers and clinicians?
The five chapters on diagnosis, prevention, and treatment are more
straightforward and clearer in their aims. However, several
controversial areas of topical importance are omitted. A more critical
appraisal from a public health perspective would have been helpful and
could have included some discussion of the relative costs and benefits
of screening with bone density measurements (or ultrasonography), the
use of dietary vitamin supplements, and the long-term roles and risks of
estrogen-replacement therapy. There are other problems, as well, that
should have been addressed: the increased risk of breast cancer in
women taking hormone-replacement therapy; the efficacy of estrogens,
which may not be as high as we previously thought; and the evidence
that estrogens provide no long-term benefit if used for only 5 to 10
years at the time of menopause. It would have been useful to have
some discussion of the advantages of treating or preventing
osteoporosis much later in life, more up-to-date coverage of the
mechanisms of action of drugs such as the bisphosphonates (the
mechanisms of which are known to vary), and the observation that only
a proportion of the efficacy of osteoporotic drugs in preventing fractures
can be explained by changes in bone density.